WO2003006045A3 - Cxcl10 treatment of secondary tissue degeneration - Google Patents

Cxcl10 treatment of secondary tissue degeneration Download PDF

Info

Publication number
WO2003006045A3
WO2003006045A3 PCT/US2002/022201 US0222201W WO03006045A3 WO 2003006045 A3 WO2003006045 A3 WO 2003006045A3 US 0222201 W US0222201 W US 0222201W WO 03006045 A3 WO03006045 A3 WO 03006045A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue degeneration
secondary tissue
cxcl10
treatment
subject
Prior art date
Application number
PCT/US2002/022201
Other languages
French (fr)
Other versions
WO2003006045A2 (en
Inventor
Hans S Keirstead
Thomas E Lane
Original Assignee
Univ California
Hans S Keirstead
Thomas E Lane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Hans S Keirstead, Thomas E Lane filed Critical Univ California
Priority to CA002452544A priority Critical patent/CA2452544A1/en
Priority to JP2003511851A priority patent/JP2005501036A/en
Priority to AU2002316674A priority patent/AU2002316674B2/en
Priority to EP02746998A priority patent/EP1411966A4/en
Publication of WO2003006045A2 publication Critical patent/WO2003006045A2/en
Publication of WO2003006045A3 publication Critical patent/WO2003006045A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a method of reducing the severity of secondary tissue degeneration associated with CNS injury in a subject by administering to a subject having secondary tissue degeneration associated with CNS injury an effective amount of a neutralizing agent specific for interferon inducible protein of 10 kDa (CXCL10).
PCT/US2002/022201 2001-07-12 2002-07-12 Cxcl10 treatment of secondary tissue degeneration WO2003006045A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002452544A CA2452544A1 (en) 2001-07-12 2002-07-12 Method for treating secondary tissue degeneration associated with central nervous system injury
JP2003511851A JP2005501036A (en) 2001-07-12 2002-07-12 CXCL10 treatment of secondary tissue degeneration
AU2002316674A AU2002316674B2 (en) 2001-07-12 2002-07-12 CXCL10 treatment of secondary tissue degeneration
EP02746998A EP1411966A4 (en) 2001-07-12 2002-07-12 Method for treating secondary tissue degeneration associated with central nervous system injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30502501P 2001-07-12 2001-07-12
US60/305,025 2001-07-12

Publications (2)

Publication Number Publication Date
WO2003006045A2 WO2003006045A2 (en) 2003-01-23
WO2003006045A3 true WO2003006045A3 (en) 2003-12-18

Family

ID=23178982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022201 WO2003006045A2 (en) 2001-07-12 2002-07-12 Cxcl10 treatment of secondary tissue degeneration

Country Status (5)

Country Link
EP (1) EP1411966A4 (en)
JP (2) JP2005501036A (en)
AU (1) AU2002316674B2 (en)
CA (1) CA2452544A1 (en)
WO (1) WO2003006045A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006045A2 (en) * 2001-07-12 2003-01-23 The Regents Of The University Of California Cxcl10 treatment of secondary tissue degeneration
KR101374514B1 (en) 2003-12-10 2014-03-13 메다렉스, 인코포레이티드 Ip-10 antibodies and their uses
JP2010013355A (en) * 2006-10-19 2010-01-21 Stelic Institute Of Regenerative Medicine Myocardial injury-controlling agent
CN101668774B (en) 2007-02-28 2013-06-26 诺维莫尼公司 Anti-ip-10 antibodies and methods of use thereof
JP5963233B2 (en) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Medicament for treating or preventing HTLV-1-related myelopathy and method for confirming therapeutic effect of antibody therapy using said medicament
EP3383903A1 (en) 2015-11-30 2018-10-10 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728377A (en) * 1993-07-20 1998-03-17 Board Of Regents, The University Of Texas System Methods and compositions incorporating IP-10
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
WO2002015932A1 (en) * 2000-08-18 2002-02-28 The Regents Of The University Of California Methods for treating demyelinating diseases
US6407209B1 (en) * 1986-04-15 2002-06-18 Novartis Ag Interferon-induced human protein in pure form, monoclonal antibodies thereto and test kits containing these antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4502408B2 (en) * 1996-09-10 2010-07-14 テオドーア−コッヒャー インスティトゥーテ CXCR3 chemokine receptor, antibody, nucleic acid and method of use
US20030166589A1 (en) * 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis
WO2003006045A2 (en) * 2001-07-12 2003-01-23 The Regents Of The University Of California Cxcl10 treatment of secondary tissue degeneration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407209B1 (en) * 1986-04-15 2002-06-18 Novartis Ag Interferon-induced human protein in pure form, monoclonal antibodies thereto and test kits containing these antibodies
US5728377A (en) * 1993-07-20 1998-03-17 Board Of Regents, The University Of Texas System Methods and compositions incorporating IP-10
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
WO2002015932A1 (en) * 2000-08-18 2002-02-28 The Regents Of The University Of California Methods for treating demyelinating diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FIFE ET AL.: "CXCL10 (INF-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis", THE JOURNAL OF IMMUNOLOGY, vol. 166, 15 June 2001 (2001-06-15), pages 7617 - 7624, XP002959570 *
LIU: "Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis", JOURNAL OF IMMUNOLOGY, vol. 167, no. 7, 1 October 2001 (2001-10-01), pages 4091 - 4097, XP002959572 *
NARUMI ET AL.: "Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis", EUR. J. IMMUNOL., vol. 32, 29 May 2002 (2002-05-29), pages 1784 - 1791, XP002959571 *
SASAKI ET AL.: "Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival", EUR J. IMMUNOL., vol. 32, 21 October 2002 (2002-10-21), pages 3197 - 3205, XP002959573 *
See also references of EP1411966A4 *
SORENSEN ET AL.: "Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system", JOURNAL OF NEUROIMMUNOLOGY, vol. 127, no. 1-2, June 2002 (2002-06-01), pages 59 - 68, XP002959574 *

Also Published As

Publication number Publication date
WO2003006045A2 (en) 2003-01-23
EP1411966A4 (en) 2005-06-01
JP2006008705A (en) 2006-01-12
AU2002316674B2 (en) 2007-09-13
EP1411966A2 (en) 2004-04-28
CA2452544A1 (en) 2003-01-23
JP2005501036A (en) 2005-01-13

Similar Documents

Publication Publication Date Title
WO2002009690A8 (en) Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent
IN2006KO01346A (en)
WO2006055526A3 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
TR200202254T2 (en) Recombinant IL-18 antagonists useful in the treatment of IL-18 induced disorders.
EP2769715A3 (en) Methods for treating autoimmune disorders, and reagents related thereto
HK1150153A1 (en) Use of pramipexole to treat amyotrophic lateral sclerosis
PT1983000E (en) Method for the treatment of multiple sclerosis by inhibiting il-17 activity
WO2001060347A3 (en) Method for treating ocular pain
WO2004045507A3 (en) Anti-angiogenic uses of il-6 antagonists
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
WO2003006045A3 (en) Cxcl10 treatment of secondary tissue degeneration
WO2003039464A3 (en) Antimuscarinic aerosol
AU8828601A (en) Methods for treating demyelinating diseases
WO2002066068A3 (en) Method of treating neurological diseases
EP1238669A3 (en) Neutrophil function inhibitors which contain glucosamine
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2003055440A8 (en) Compositions and methods for the treatement of immune related diseases
WO2003057719A3 (en) Methods of modulating localization and physiological function of ip3 receptors
WO2003103699A8 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
WO2003024996A3 (en) Antibacterial macrocycles
WO2002072098A8 (en) Method of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2452544

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002746998

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003511851

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002316674

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002746998

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642